ArticleJournal of medical case reports2026
Reversible bilateral sensorineural hearing loss associated with atorvastatin: a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtorvastatin is widely prescribed for hyperlipidemia and is generally well tolerated. Auditory adverse effects are rarely reported, and statin-associated sensorineural hearing loss (SNHL) remains poorly characterized. CASE PRESENTATION: A 45-year-old Ethiopian woman developed bilateral tinnitus followed by progressive, symmetric bilateral SNHL 3 weeks after starting atorvastatin 40 mg daily. She had no other ototoxic risk factors. Pure-tone audiometry confirmed bilateral moderate SNHL. Given the temporal association and exclusion of alternatives, atorvastatin was discontinued. One week later, audiometry showed improvement to mild hearing loss, and at a 1-month follow-up, thresholds normalized with complete symptom resolution. She was subsequently switched to rosuvastatin 20 mg daily, with no recurrence at a 6-month follow-up.
conclusionThis case demonstrates that atorvastatin-associated SNHL can be reversible when recognized early. Prompt identification of new auditory symptoms and timely discontinuation of the offending medication may prevent permanent hearing impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.